Antihypertensive Combination Treatment: State of the Art

Current Hypertension Reports

Volumn 17, Issue 7, 2015, Pages

  Burnier, M ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Adherence; Angiotensin blockers; Calcium channel blockers; Diuretics; Single pill combination

Indexed keywords

ALPHA BLOCKER PLUS DIURETIC AGENT; ANGIOTENSIN CONVERTING ENZYME INHIBITOR PLUS CALCIUM CHANNEL BLOCKER; ANGIOTENSIN CONVERTING ENZYME INHIBITOR PLUS CALCIUM CHANNEL BLOCKER PLUS DIURETIC AGENT; ANGIOTENSIN CONVERTING ENZYME INHIBITOR PLUS DIURETIC AGENT; ANGIOTENSIN RECEPTOR BLOCKER PLUS CALCIUM CHANNEL BLOCKER; ANGIOTENSIN RECEPTOR BLOCKER PLUS CALCIUM CHANNEL BLOCKER PLUS DIURETIC AGENT; ANGIOTENSIN RECEPTOR BLOCKER PLUS DIURETIC AGENT; ANTIHYPERTENSIVE AGENT; BETA BLOCKER PLUS CALCIUM CHANNEL BLOCKER; BETA BLOCKER PLUS DIURETIC AGENT; NADOLOL; RENIN INHIBITOR PLUS CALCIUM CHANNEL BLOCKER; RENIN INHIBITOR PLUS CALCIUM CHANNEL BLOCKER PLUS DIURETIC AGENT; RENIN INHIBITOR PLUS DIURETIC AGENT; THIAZIDE DIURETIC AGENT PLUS POTASSIUM SPARING DIURETIC AGENT; UNCLASSIFIED DRUG; DRUG COMBINATION;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CONTROLLED CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; HUMAN; HYPERTENSION; MEDICATION COMPLIANCE; MONOTHERAPY; PHARMACOLOGICAL PARAMETERS; PILL BURDEN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SINGLE PILL COMBINATION; SINGLE PILL DUAL COMBINATION; SINGLE PILL TRIPLE COMBINATION; BLOOD PRESSURE; DRUG COMBINATION; DRUG EFFECTS; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG COMBINATIONS; HUMANS; HYPERTENSION; TREATMENT OUTCOME;

EID: 84931272663     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-015-0562-0     Document Type: Review

References (63)

1. Waeber B, Brunner HR. Combination antihypertensive therapy: does it have a role in rational therapy? Am J Hypertens. 1997;10(7 Pt 2):131S–7.
2. Tocci G, Ferrucci A, Guida P, Avogaro A, Comaschi M, Corsini A, et al. An analysis of the management of cardiovascular risk factors in routine clinical practice in Italy: an overview of the main findings of the EFFECTUS study. High Blood Press Cardiovasc Prev Off J Ital Soc Hypertens. 2011;18(1):19–30.
3. Blonde L, San Juan ZT, Bolton P. Fixed-dose combination therapy in type 2 diabetes mellitus. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2014;20(12):1322–32.
4. Malerba M, Morjaria JB, Radaeli A. Differential pharmacology and clinical utility of emerging combination treatments in the management of copd—role of umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis. 2014;9:687–95.
5. Thompson MA, Mugavero MJ, Amico KR, Cargill VA, Chang LW, Gross R, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an international association of physicians in aids care panel. Ann Intern Med. 2012;156(11):817–33. W-284, W-285, W-286, W-287, W-288, W-289, W-290, W-291, W-292, W-293, W-294.
6. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 esh/esc guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the european society of hypertension (esh) and of the european society of cardiology (esc). J Hypertens. 2013;31(7):1281–357.
7. Brunner HR, Menard J, Waeber B, Burnier M, Biollaz J, Nussberger J, et al. Treating the individual hypertensive patient: considerations on dose, sequential monotherapy and drug combinations. J Hypertens. 1990;8(1):3–11. discussion 13–19.
8. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens. 2002;4(6):393–404.
9. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (hot) randomised trial. Hot study group. Lancet. 1998;351(9118):1755–62.
10. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417–28.
11. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125(9):882–887 e881. Very interesting paper on the issue of drug adherence in primary and secondary prevention demonstrating the true problems in real life.
12. Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med. 2007;167(2):141–7.
13. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43(1):10–7.
14. Neuhauser HK, Adler C, Rosario AS, Diederichs C, Ellert U. Hypertension prevalence, awareness, treatment and control in Germany 1998 and 2008–11. J Hum Hypertens. 2015;29(4):247–53.
15. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The department of veterans affairs cooperative study group on antihypertensive agents. N Engl J Med. 1993;328(13):914–21.
16. Bronsert MR, Henderson WG, Valuck R, Hosokawa P, Hammermeister K. Comparative effectiveness of antihypertensive therapeutic classes and treatment strategies in the initiation of therapy in primary care patients: a distributed ambulatory research in therapeutics network (DARTNet) study. J Am Board Fam Med JABFM. 2013;26(5):529–38. An interesting survey on the efficacy of various therpauetic strategies of hypertension in promary care settings.
17. Mourad JJ, Waeber B, Zannad F, Laville M, Duru G, Andrejak M, et al. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. J Hypertens. 2004;22(12):2379–86.
18. Schafer HH, Sudano I, Theus GR, Noll G, Burnier M. Target blood pressure attainment with antihypertensive therapy in swiss primary care. Blood Press. 2012;21(4):211–9.
19. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3):290–300.
20. Kochar M, Guthrie R, Triscari J, Kassler-Taub K, Reeves RA. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens. 1999;12(8 Pt 1):797–805.
21. Burnier M, Vuignier Y, Wuerzner G. State-of-the-art treatment of hypertension: established and new drugs. Eur Heart J. 2014;35(9):557–62.
22. Krause T, Lovibond K, Caulfield M, McCormack T, Williams B, Guideline Development G. Management of hypertension: summary of nice guidance. BMJ. 2011;343:d4891.
23. Armstrong C. JNC8 guidelines for the management of hypertension in adults. Am Fam Physician. 2014;90(7):503–4.
24. Alderman MH, Piller LB, Ford CE, Probstfield JL, Oparil S, Cushman WC, et al. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2012;59(5):926–33.
25. Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB. Hypokalemia associated with diuretic use and cardiovascular events in the systolic hypertension in the elderly program. Hypertension. 2000;35(5):1025–30.
26. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS Study: intervention as a goal in hypertension treatment (insight). Lancet. 2000;356(9227):366–72.
27. Bobrie G, Frank M, Azizi M, Peyrard S, Boutouyrie P, Chatellier G, et al. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens. 2012;30(8):1656–64.
28. MacKay JH, Arcuri KE, Goldberg AI, Snapinn SM, Sweet CS. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med. 1996;156(3):278–85.
29. Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension. 2012;59(6):1110–7.
30. Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. Meta-analysis of dose–response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension. 2012;59(6):1104–9.
31. Patel A, Group AC, MacMahon S, Chalmers J, Neal B, Woodward M, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the advance trial): a randomised controlled trial. Lancet. 2007;370(9590):829–40.
32. Mogensen CE, Viberti G, Halimi S, Ritz E, Ruilope L, Jermendy G, et al. Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: premier. Hypertension. 2003;41(5):1063–71.
33. Sica D, Bakris GL, White WB, Weber MA, Cushman WC, Huang P, et al. Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J Clin Hypertens. 2012;14(5):284–92.
34. Bakris GL, Sica D, White WB, Cushman WC, Weber MA, Handley A, et al. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med. 2012;125(12):1229 e1221–10.
35. Cushman WC, Bakris GL, White WB, Weber MA, Sica D, Roberts A, et al. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension. 2012;60(2):310–8.
36. Makani H, Bangalore S, Romero J, Htyte N, Berrios RS, Makwana H, et al. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate–a meta-analysis of randomized trials. J Hypertens. 2011;29(7):1270–80.
37. de la Sierra A. Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system. J Hum Hypertens. 2009;23(8):503–11.
38. Bakris GL, Sarafidis PA, Weir MR, Dahlof B, Pitt B, Jamerson K, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (accomplish): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010;375(9721):1173–81.
39. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the anglo-scandinavian cardiac outcomes trial-blood pressure lowering arm (ascot-bpla): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895–906.
40. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The international verapamil-trandolapril study (invest): a randomized controlled trial. JAMA. 2003;290(21):2805–16.
41. Bakris G, Molitch M, Zhou Q, Sarafidis P, Champion A, Bacher P, et al. Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the star-let study. J Cardiometab Syndr. 2008;3(1):18–25.
42. Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, et al. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the accomplish randomised controlled trial. Lancet. 2013;381(9866):537–45.
43. Stergiou GS, Makris T, Papavasiliou M, Efstathiou S, Manolis A. Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy. J Hypertens. 2005;23(4):883–9.
44. Mann JF, Anderson C, Gao P, Gerstein HC, Boehm M, Ryden L, et al. Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial. J Hypertens. 2013;31(2):414–21.
45. Campbell DJ, McGrady M, Prior DL, Coller JM, Boffa U, Shiel L, et al. Most individuals with treated blood pressures above target receive only one or two antihypertensive drug classes. Intern Med J. 2013;43(2):137–43.
46. Basile J, Neutel J. Overcoming clinical inertia to achieve blood pressure goals: the role of fixed-dose combination therapy. Ther Adv Cardiovasc Dis. 2010;4(2):119–27.
47. Lanier G, Sankholkar K, Aronow WS. Azilsartan, aliskiren, and combination antihypertensives utilizing renin-angiotensin-aldosterone system antagonists. Am J Ther. 2014;21(5):419–35.
48. Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the trinity multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther. 2010;32(7):1252–69.
49. Lacourciere Y, Taddei S, Konis G, Fang H, Severin T, Zhang J. Clinic and ambulatory blood pressure lowering effect of aliskiren/amlodipine/hydrochlorothiazide combination in patients with moderate-to-severe hypertension: a randomized active-controlled trial. J Hypertens. 2012;30(10):2047–55.
50. Toth K, Investigators P. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the pianist study (perindopril-indapamide plus amlodipine in high risk hypertensive patients). Am J Cardiovasc Drugs. 2014;14(2):137–45.
51. Weir MR, Hsueh WA, Nesbitt SD, Littlejohn 3rd TJ, Graff A, Shojaee A, et al. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil +/− hydrochlorothiazide. J Clin Hypertens. 2011;13(6):404–12.
52. Taddei S. Fixed-dose combination therapy in hypertension: pros. High Blood Press Cardiovasc Prev Off J Ital Soc Hypertens. 2012;19(2):55–7. An intersting debate on the pros and cons of using fixed-dose combinations in the, anagement of hypertension. Assocaited with the paper of ANgeli et al. below.
53. Angeli F, Reboldi G, Mazzotta G, Garofoli M, Ramundo E, Poltronieri C, et al. Fixed-dose combination therapy in hypertension: cons. High Blood Press Cardiovasc Prev Off J Ital Soc Hypertens. 2012;19(2):51–4.
54. Burnier M. Fixed combinations in the pragmatic management of hypertension: focus on aliskiren and hydrochlorothiazide as a single pill. Integr Blood Press Control. 2010;3:57–62.
55. Burnier M, Wuerzner G, Struijker-Boudier H, Urquhart J. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension. 2013;62(2):218–25. A careful review of the different techniques of measuring and analysing adherence data with a description of all the pitfalls and limits of the various available techniques.
56. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336(7653):1114–7.
57. Kizilirmak P, Berktas M, Uresin Y, Yildiz OB. The efficacy and safety of triple vs dual combination of angiotensin ii receptor blocker and calcium channel blocker and diuretic: a systematic review and meta-analysis. J Clin Hypertens. 2013;15(3):193–200.
58. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713–9.
59. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399–407.
60. Halpern MT, Khan ZM, Schmier JK, Burnier M, Caro JJ, Cramer J, et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension. 2006;47(6):1039–48.
61. Burnier M, Brede Y, Lowy A. Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesartan and ramipril. Int J Clin Pract. 2011;65(2):127–33.
62. Tung YC, Lin YS, Wu LS, Chang CJ, Chu PH. Clinical outcomes and healthcare costs in hypertensive patients treated with a fixed-dose combination of amlodipine/valsartan. J Clin Hypertens. 2015;17(1):51–8.
63. Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens. 2011;29(3):610–8.